Please be aware that the information provided is a summary of select releases made to the ASX, as evaluated and interpreted by ASX Briefs. It is important to thoroughly read the entire original release before forming an opinion, rather than relying solely on the brief overview presented here. ASX Briefs is not associated with the ASX. ASX Briefs is an experimental AI project incorporating chatGPT, and as such, does not guarantee the accuracy of the information provided.
Osteopore announces a strategic sub-distribution partnership with Kelyniam through its U.S. sales distribution partner, Bioplate Inc., to further penetrate the cranial implant market.
Kelyniam specializes in custom prosthetics production and will focus on securing sales in approximately 20 hospitals across 8 states, including prestigious institutions like Johns Hopkins Hospital and Boston Medical Center.
Osteopore products have FDA clearance and are available in the U.S., with the partnership expected to enhance market penetration and contribute to future growth.